Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. [electronic resource]
Producer: 20170824Description: 770-778 p. digitalISSN:- 1474-5488
- Abdominal Pain -- chemically induced
- Adenocarcinoma -- drug therapy
- Aged
- Anemia -- chemically induced
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Camptothecin -- administration & dosage
- Caprylates -- administration & dosage
- Female
- Fluorouracil -- administration & dosage
- Hematologic Diseases -- chemically induced
- Humans
- Hyperglycemia -- chemically induced
- Hypoalbuminemia -- chemically induced
- Hypokalemia -- chemically induced
- Irinotecan
- Leucovorin -- administration & dosage
- Lymphopenia -- chemically induced
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neutropenia -- chemically induced
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Pancreatic Neoplasms -- drug therapy
- Sensation Disorders -- chemically induced
- Sepsis -- chemically induced
- Sulfides -- administration & dosage
- Thrombocytopenia -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.